Group B+ Conflicting Applications Work Stream:
Study on Usage of Secret Prior Art in Patentability Determinations

Members of the Work Stream:
Canada, the European Patent Office, Japan, Korea, Sweden, and the United Kingdom
I. Introduction

An important issue relevant to patent law harmonization and work-sharing among patent offices is the extent to which “conflicting applications” qualify as prior art against pending patent applications. Applications are said to conflict when an earlier-filed application containing the same subject matter claimed in an application later filed in that same office publishes after the filing date of the later-filed application. Because the earlier application does not become publicly available until its publication date, which is after the filing date of the later application, it is not prior art, in the typical sense, against that application. Absent a rule for addressing this conflict, the result would be the issuance of two patents directed to the same or substantially the same subject matter.

To prevent the issuance of multiple patents on the same invention, each patent system has adopted general rules that give prior art effect to the earlier-filed application as of its filing or priority date, upon publication, notwithstanding that it was held in secrecy at the patent office at the time the later application was filed. This legal fiction is commonly referred to as “secret prior art” (SPA) because the information is contained in publicly unavailable patent applications, but treated as prior art nonetheless to avoid the grant of multiple patents for the same invention. The use of the terms “conflicting applications,” “secret prior art,” and “SPA” are used interchangeably throughout this paper.

While all patent systems have laws and practices addressing to what extent “secret prior art” qualifies as prior art, there are substantial variations among jurisdictions as to its application and effect. Group B+ and the Tegernsee Group have been studying this issue and the various practices for several years, with a view to developing a harmonized approach.

In 2015, the B+ Sub-Group on Patent Harmonization issued an “Objectives and Principles” paper (B+/SG/2/10) that identifies, among other things, the following agreed principles regarding conflicting applications:

(i) The grant of multiple patents for the same invention in the same jurisdiction should be prevented;

(ii) The patent system should allow for the protection of incremental inventions while ensuring that patent rights are not unjustifiably extended;

(iii) Any system which allows incremental inventions to be patented should:

   (a) balance the interests of inventors to protect incremental improvements on their own inventions with the interests of third parties to operate in the same field; and,
(b) promote innovation and competition.

The “Objectives and Principles” paper further identifies related issues for which there is a consensus view. Of particular relevance here, the B+ Sub-Group recommended that “[f]urther work should be conducted to compare various alternative approaches, bearing in mind the effects on innovation and competition.” This paper follows that recommendation and builds on prior work by presenting new empirical data on conflicting application practices in different offices.

With a view toward developing a harmonized approach to the treatment of secret prior art, this Work Stream proposed a study to evaluate the impact of secret prior art in patentability determination in participating offices. This paper provides an overview of the parameters and methodology of this study; presents key findings by participating offices on the frequency and type of secret prior art rejections; and offers a preliminary analysis of the empirical data.

II. Legal Background

All patent systems have practices setting forth to what extent conflicting applications are available as prior art. Applications are said to conflict when an earlier-filed application containing the same subject matter claimed in an application later filed in that same office publishes after the filing date (or priority date, if applicable) of the later-filed application. In such cases, the earlier application is not prior art to the later application because it did not become publicly available until it published, i.e., after the later application’s filing date (or priority date, if applicable). This creates a conflict because, absent another ground of refusal, both applications would be patentable, and thus two patents would issue on the same or substantially the same subject matter.

To prevent this, each patent system has adopted a general rule that gives prior art effect to the earlier-filed application as of its filing or priority date, upon publication, thereby creating this legal fiction known as “secret prior art.” Jurisdictions vary, however, in the application and effect of this general rule.

One major difference is in the prior art effect of the earlier application. In the United States, “secret prior art” can be the basis for refusing an application for both lack of novelty and obviousness (inventive step). Under the European Patent Convention, “secret prior art” can only be used to refuse an application for lack of novelty; it cannot be cited alone or in combination with any other reference to show lack of an inventive step. In Japan, the practice seems to be in between the United States and Europe: “secret prior art” can be used to refuse an application for lack of novelty, including minor differences within the common general knowledge of one of ordinary skill in the art, but it cannot be used to refuse an application for lack of inventive step. Other jurisdictions generally follow one of these three basic approaches.

Another significant difference in practices is the applicable rule when the earlier application and the later application were filed by, owned by, or subject to a relevant agreement between the
same entities. To address this situation, some jurisdictions have adopted rules to prevent “self-collision,” in which the applicant’s own earlier applications are deemed not to “collide” (conflict) with his later one. This practice is commonly referred to as anti-self-collision. In contrast, self-collision refers to the practice in which the same applicant is precluded from obtaining a patent because of his or her own conflicting prior art. Once again, the United States, Europe, and Japan generally cover the spectrum of practices. Anti-self-collision applies in the United States and Japan, but does not in Europe. Other jurisdictions fall into one of these two categories.

The following section provides a more detailed explanation of the laws and practices governing the application and use of conflicting applications in patentability assessments for the five jurisdictions that participated in this study: Canada, Europe, Japan, South Korea (hereinafter “Korea”), and the United States.

III. Relevant Statutory Provisions of Work Stream Participants

1. Canada

Pursuant to paragraphs 28.2(1)(c) and (d) of the Canadian Patent Act, the subject matter of a claim must not have been previously disclosed in an application for a patent that is filed in Canada by a person other than the applicant and that has a filing date or a priority date that is before the filing date or any applicable priority date of the relevant claim.

Simply stated, any relevant material disclosed in a Canadian patent application that is filed by a person other than the applicant and that has a filing date or any applicable priority date that is before the filing date or the applicable priority date of the claim may be cited as novelty-destroying prior art.

Whether the subject matter disclosed in a co-pending application had been made available to the public or not before the filing of a pending application is not relevant to the determination of whether it is citable under paragraph 28.2(1)(c) or (d). In practice, however, prior art that is still secret when it is identified will only be cited once it has been published.

Setting aside the cases of double patenting described below, the general rule in Canada is that secret prior art can only be used in making lack of novelty rejections and cannot be cited to support an obviousness objection.

Canadian case law provides a prohibition against double patenting. An applicant cannot be granted more than one patent in respect of the same invention. A claim included in a co-pending application that discloses the subject matter claimed in the pending application but that would not be citable for lack of novelty under paragraph 28.2(1)(c) or (d) because both applications were filed by the same applicant would constitute a bar under the doctrine of double patenting.
The prohibition against double patenting further extends to obviousness objections based on subject matter disclosed in the claims of a co-pending application. However, it is not permissible to combine multiple prior art citations to make an obviousness double-patenting rejection (i.e., Canada has a “no-mosaic” approach to such obviousness rejections). Furthermore, co-pending applications cited in support of double-patenting obviousness may or may not be secret at the filing date or any applicable priority date of the relevant application.

2. **Europe**

Under the European Patent Convention (EPC), the content of European applications that are filed prior to the filing or priority date of the application being examined, and which are published by virtue of Article 93 of the EPC on or after that date, are included pursuant to Article 54(3) of the EPC in the state of the art for the purpose of assessing novelty of the invention. However, as explicitly set forth in the second sentence of Article 56 of the EPC, such applications are not considered to form part of the state of the art for the purpose of determining whether there has been an inventive step.

The EPC does not provide for anti-self-collision. This means that, at the EPO, conflicting applications are applied in the same manner regardless of whether the earlier and later applications were filed by different entities or by the same applicant.

In the United Kingdom (UK), sections 2 and 3 of the Patents Act 1977 are framed to have the same effect in the UK as Articles 54 and 56 of the EPC respectively. Therefore, the law governing conflicting applications in the UK is equivalent to that outlined above in respect of the EPC. For an application to be considered secret prior art under UK law it must be either a UK national application or a European application (including PCT applications which have entered either the UK national phase or the European regional phase).

3. **Japan**

Article 29bis of the Japan Patent Act states that no patent shall be granted for an invention claimed in a patent application which is “identical” to the matter disclosed in an earlier application. The scope of the term “identical” in Article 29bis includes cases in which there is no difference between the claimed invention and the matter disclosed in the earlier application, as well as when there is only a “minor difference,” such as differences in the embodiments of the means for solving the problem, when the effects produced are not markedly different, and when the subject matter can be derived by a person skilled in the art, considering common general knowledge at the filing date of that application. “Minor differences” may also include equivalents, if they would be easily understood by a person skilled in the art. Please see Appendix 1 for a more detailed explanation of JPO’s practice.
Article 29bis also provides for anti-self-collision when the same person files both applications. Anti-self-collision is limited, however, by virtue of Article 39, which prevents two patents from issuing where they claim the same invention.

4. Korea

The approach to the use of conflicting applications in Korea is similar to that of Japan. Article 29(3) of the Korean Patent Act provides the general rule on conflicting applications, which prevents a patent from issuing on a subsequent application when an earlier-filed, later-published application identically or substantially identically discloses the invention claimed in the subsequent application. As with the law in Japan, Article 29(3) limits application of this rule where the inventors or applicants identified in the two applications are the same. Please see Appendix 2 for a more detailed explanation of KIPO’s practice.

Similar to the approach of Japan, Article 36 of the Korean Patent Act prevents double patenting when the applications in question claim identical or substantially identical inventions. Unlike Article 29(3), Article 36 also applies to applications from same inventor or applicant (no anti-self-collision) and applications filed on the same date.

5. United States

The America Invents Act (AIA) made a number of changes to U.S. law regarding the treatment of conflicting applications. Perhaps the most significant change was the abolishment of the Hilmer doctrine. Under the Hilmer doctrine, pre-AIA 35 U.S.C. § 102(e) limited the effective filing date for U.S. patents (and published applications) as prior art to their earliest U.S. filing date. In contrast, AIA 35 U.S.C. § 102(d) provides that if the U.S. patent document claims priority to one or more prior-filed foreign or international applications, the patent or published application was effectively filed on the filing date of the earliest such application that describes the subject matter. Therefore, if the subject matter relied upon is described in the application to which there is a priority or benefit claim, the U.S. patent document is effective as prior art as of the filing date of the earliest such application, regardless where filed.

The treatment of conflicting applications in the United States is governed, in part, by 35 U.S.C. § 102(a)(2), which provides that a claimed invention is patentable unless the claimed invention was described in a patent or in a published patent application that names another inventor and was effectively filed before the effective filing date of the claimed invention. This legal authority prevents patents from issuing on later-filed applications when an earlier-filed application by another inventor discloses the claimed invention.

In contrast to the laws of the other participating jurisdictions, in the United States conflicting applications may be considered by themselves or in combination with other items of “prior art,” including other conflicting applications, for purposes of determining whether an invention in a later-filed application would have been obvious. The section governing obviousness, 35 U.S.C.
§ 103, provides that a patent for a claimed invention may not be obtained if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Because all the subject matter that is prior art under Section 102 can be used for obvious determinations under Section 103, the prior art effect of conflicting applications is the same for deterring lack of novelty and obviousness. Please see Appendix 3 for a more detailed explanation of USPTO’s practice.

There are two legal mechanisms under U.S. law to address double patenting. The first is a statutory prohibition on the same inventive entity obtaining more than one patent containing claims of identical scope. Section 101 of Title 35 has been interpreted to limit applicants to “a single patent” per claimed invention.

The second vehicle is the judicially created doctrine of non-statutory double patenting. Claims in a later-filed pending application that are “patentably indistinct” from the claims in a co-pending application by or patent granted to the same inventive entity will be refused. In this context, patentably indistinct inventions are those inventions that are neither novel nor non-obvious in view of the conflicting prior art. However, the applicant can overcome this ground of double-patenting by filing a “terminal disclaimer.” This disclaimer has two main features. The first is the “terminal” provision, which disclaims the portion of the patent term of the pending application that would extend beyond the expiration date of the patent term of the conflicting application or patent. This assures that the applicant does not obtain an unjust timewise extension of patent rights based on claims of patentably indistinct scope emanating from different applications subject to different patent terms. The second feature of the disclaimer is the requirement that all of the applications/patents involved must be commonly owned. The purpose of this common ownership provision is to prevent infringers from being subjected to multiple lawsuits from different parties holding patents of overlapping scope.

IV. Goals and Methodology of Study on the Usage of Secret Prior Art

The goal of this study is to determine how often and in what manner examiners apply “secret prior art” in patentability assessments across various technology sectors, according to the different practices represented by the offices participating in this work stream. By providing first-of-its-kind empirical data and analysis of secret prior art usage among offices, this study will provide important and heretofore missing context to Group B+ discussions on the different approaches to conflicting applications.

To ensure consistency, the participating offices agreed to the following basic methodology for this study:
1. Each office will randomly select at least 100 applications in each of the following technology areas, where such applications had received only a first examination on the merits conducted in calendar year 2015: 1. Biotechnology and Chemistry (e.g., Organic Chemistry, Chemical and Materials Engineering, Pharmaceuticals), 2. Electrical (e.g., Computer Architecture, Software, Computer Networks, Communications, Semiconductors, Electrical and Optical Systems and Components), and 3. Mechanical (e.g., Manufacturing, Products, Agriculture, Mechanical Engineering).

2. The selected applications will be reviewed to determine the number of applications containing a refusal made under the respective “secret prior art” provisions applicable in that jurisdiction. When possible, the type of refusal (i.e., lack of novelty or obviousness) made by the examiner and the number of references used to refuse the claim(s) at issue were also recorded.

3. When possible, the number of instances when an application was refused based on secret prior art by the same inventor/applicant will be recorded, and the applicability of anti-self-collision will be indicated.

Due to different sampling capabilities and legal provisions across the offices, the actual methodology employed by each office may vary slightly from the above-noted general framework, somewhat complicating a comparative analysis. Such variances are explained for each office in the presentation of its data in the “Results and Findings” section of this paper, below.

V. Results and Findings

The results of this study focus on how frequently and on what basis examiners apply “secret prior art” in refusing applications across the biotechnology and chemistry, electrical, and mechanical technology areas. Each jurisdiction’s results are presented below and then are analyzed collectively in Section IV, “Preliminary Analysis of Results.”

a. Canada

The Canadian Intellectual Property Office (CIPO) individually analyzed each substantive patentability report and identified every instance in which a piece of secret prior art is cited in support of an objection. As described in the previous section, in Canada secret prior art can be cited in support of either an anticipation objection under paragraph 28.2(1)(c) or (d) of the Patent Act or a double-patenting objection. CIPO analyzed 1,750 randomly selected first substantive reports issued in 2015. Cases in which anti-self-collision provisions applied could not be tallied as Canadian examiners do not raise or note those instances.
According to Canadian patent law, double-patenting objections do not only rely on secret prior art. Instead, these objections may rely on prior art that has been disclosed prior to the filing date (or an applicable priority date) of the relevant application and may even rely on co-pending applications whose filing or priority date is posterior to the relevant application’s filing or priority date. However, in order to focus the analysis strictly on the use of secret prior art, double-patenting objection results were refined to eliminate all instances in which the co-pending application cited had been published before the filing date (or priority date where applicable) of the relevant application, as well as cases in which the filing date or priority date of the co-pending application cited is posterior to the relevant application’s filing date or priority date.

Within the cases analyzed, the prior art search was found to have been deferred in a small number of cases. These have been identified and excluded from the final count and the sample size corrected in order to more precisely adhere to the methodology proposed in the study outline. Finally, as noted in the preceding section, in Canada, double-patenting objections may be based on either anticipation or obviousness. In the case of double-patenting obviousness, however, objections do not combine multiple prior art citations.

Tables 1 and 2 summarize CIPO’s findings, taking into account the exclusions and caveats discussed in the preceding paragraphs.

Table 1: Canadian Intellectual Property Office’s Secret Prior Art Rejections in 2015, by Technology Area

<table>
<thead>
<tr>
<th>Technology</th>
<th>Initial Sample Size</th>
<th>Deferred Searches</th>
<th>Corrected Sample Size</th>
<th>Number of SPA Objections (Novelty)</th>
<th>Total % of SPA Rejections¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology</td>
<td>250</td>
<td>28</td>
<td>222</td>
<td>2</td>
<td>0.90%</td>
</tr>
<tr>
<td>General Chemistry</td>
<td>250</td>
<td>7</td>
<td>243</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>Organic Chemistry</td>
<td>250</td>
<td>16</td>
<td>234</td>
<td>4</td>
<td>1.71%</td>
</tr>
<tr>
<td>Electrical</td>
<td>500</td>
<td>38</td>
<td>462</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>Mechanical</td>
<td>500</td>
<td>31</td>
<td>469</td>
<td>5</td>
<td>1.07%</td>
</tr>
<tr>
<td>Total</td>
<td>1750</td>
<td>120</td>
<td>1630</td>
<td>11</td>
<td>.67%</td>
</tr>
</tbody>
</table>

¹ Objections made under Canadian Patent Act 28.2(1)(c) or (d).
Table 2: Canadian Intellectual Property Office’s Secret Prior Art Double Patenting Rejections in 2015, by Technology Area

<table>
<thead>
<tr>
<th>Technology</th>
<th>Initial Sample Size</th>
<th>Deferred Searches</th>
<th>Corrected Sample Size</th>
<th>Double-Patenting SPA Rejections (Novelty)</th>
<th>% of Double-Patenting SPA Rejections (Novelty)</th>
<th>Number of Double-Patenting SPA Rejections (Inventive Step)</th>
<th>% of Double-Patenting SPA Rejections (Inventive Step)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology</td>
<td>250</td>
<td>28</td>
<td>222</td>
<td>2</td>
<td>0.90%</td>
<td>8</td>
<td>3.60%</td>
</tr>
<tr>
<td>General Chemistry</td>
<td>250</td>
<td>7</td>
<td>243</td>
<td>1</td>
<td>0.41%</td>
<td>7</td>
<td>2.88%</td>
</tr>
<tr>
<td>Organic Chemistry</td>
<td>250</td>
<td>16</td>
<td>234</td>
<td>5</td>
<td>2.14%</td>
<td>8</td>
<td>3.42%</td>
</tr>
<tr>
<td>Electrical</td>
<td>500</td>
<td>38</td>
<td>462</td>
<td>2</td>
<td>0.43%</td>
<td>9</td>
<td>1.95%</td>
</tr>
<tr>
<td>Mechanical</td>
<td>500</td>
<td>31</td>
<td>469</td>
<td>3</td>
<td>0.64%</td>
<td>5</td>
<td>1.07%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1750</strong></td>
<td><strong>120</strong></td>
<td><strong>1630</strong></td>
<td><strong>13</strong></td>
<td><strong>0.80%</strong></td>
<td><strong>37</strong></td>
<td><strong>2.27%</strong></td>
</tr>
</tbody>
</table>

b. European Patent Office

The European Patent Office (EPO) selected 200 cases in each technology area: chemistry, electrical, and mechanical, in which either a search opinion or a first communication was issued in 2015.

An automated process was run to find applications in which “secret prior art” (category “P” and “E”) documents had been cited. Those applications found to have “P” or “E” citations were then checked to find: (a) the number of applications containing objections based on secret prior art in the search opinion or in the first examination report; and (b) the number of those secret prior art citations from the same applicant. Secret prior art citations, cited under Article 54(3) EPC may only be cited for novelty. Therefore, references to them in a search opinion or examination report will only be in relation to assessing novelty, not inventive step.

The secret prior art objection raised by the examiner is usually only one of the objections raised in the search opinion or first communication, and does not usually lead to a refusal of the application at the EPO, as applicants usually are able to modify their claims to circumvent the objection.

Table 3 provides the number of applications containing objections based on secret prior art per technology area.
Double patenting at the EPO requires that both applications be filed by the same applicant and have the same priority or filing date, thus Table 3 does not contain information about double patenting objections.

**Table 3: European Patent Office’s Applications with Objections Based on Secret Prior Art at Search Opinion/First Communication Stage in 2015, by Technology Area**

<table>
<thead>
<tr>
<th>Technology</th>
<th>Sample Size</th>
<th>Number of cases with SPA objections in search opinion or first communication</th>
<th>% of cases with SPA objections (54(3) EPC, Novelty)</th>
<th>Number of citations from same applicant</th>
<th>% of cases with same applicant SPA citations/objections</th>
<th>% of SPA citations which are from same applicant</th>
<th>Total % of cases with SPA objections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemistry</td>
<td>200</td>
<td>12</td>
<td>6%</td>
<td>6</td>
<td>3%</td>
<td>50%</td>
<td>6%</td>
</tr>
<tr>
<td>Electrical</td>
<td>200</td>
<td>5</td>
<td>2.5%</td>
<td>3</td>
<td>1.5%</td>
<td>60%</td>
<td>2.5%</td>
</tr>
<tr>
<td>Mechanical</td>
<td>200</td>
<td>6</td>
<td>3%</td>
<td>4</td>
<td>2%</td>
<td>67%</td>
<td>3%</td>
</tr>
<tr>
<td>Total</td>
<td>600</td>
<td>23</td>
<td>3.83%</td>
<td>13</td>
<td>2.17%</td>
<td>56.5%</td>
<td>3.83%</td>
</tr>
</tbody>
</table>

c.  Japan

The Japan Patent Office (JPO) randomly selected 200 cases from each of the following technology areas: (1) Chemistry, Life Science, and Material Science, (2) Electronic, and (3) Mechanical technology sectors. An automated process was run to find applications in which rejections applying “secret prior art” was applied. Those applications were then individually reviewed for three criteria: (1) to find the number of applications containing secret prior art rejections in the first notice of reasons for refusal; (2) the number of secret prior art references relied upon in each rejection; and (3) the number of applications in which secret prior art references filed by the same applicant were relied upon to reject the claims.

Under Article 29bis of the Japan Patent Act, an earlier application that has been published after the filing of a later application (“secret prior art”) may serve as the basis for a reason for refusal when a claimed invention in the later application is identical to the matter stated in the description of the earlier application as filed. Because Japan follows an enlarged novelty approach, “identical” includes not only a case in which there are no differences between the claimed invention and the matter stated in the earlier application, but also a case in which, although there are differences, such differences are minor ones in embodying the solution of the technical problem. In these cases, the later invention is deemed “substantially the same” as the claimed invention of the earlier filed application. In addition, pursuant to Article 39(1) of the Japan Patent Act, a prior application may be the basis for ground for refusal on a claim-by-claim basis to prevent double patenting.

Table 4 provides data for the frequency for which rejections are based on secret prior art. It should be noted that, since anti–self collision is adopted in Article 29bis, the numbers of secret
prior art references filed by the same applicant constituting the grounds for a reason for refusal under Article 29bis are always zero.

The JPO was not able to count the number of cases in which anti-self-collision applied because JPO examiners do not record any application of anti–self collision except when reasons for refusal under Article 39(1) are raised relying upon a claim in self-colliding applications.

Table 4 summarizes the JPO’s findings on the number of applications rejected based on secret prior art at the first examination stage.

**Table 4: Japan Patent Office’s Secret Prior Art Rejections in 2015, by Technology Area**

<table>
<thead>
<tr>
<th>Technology</th>
<th>Sample Size</th>
<th>Number of SPA Rejections Under Article 29bis (Novelty)</th>
<th>% of SPA Rejections (Novelty)</th>
<th>Number of SPA Rejections Under Article 39(1)</th>
<th>% of Double Patenting SPA Rejections</th>
<th>Total % of SPA Rejections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemistry, Life Science and Material Science</td>
<td>200</td>
<td>5</td>
<td>2.50%</td>
<td>0</td>
<td>0.00%</td>
<td>2.50%</td>
</tr>
<tr>
<td>Electronic Technology</td>
<td>200</td>
<td>10</td>
<td>5.00%</td>
<td>0</td>
<td>0.00%</td>
<td>5.00%</td>
</tr>
<tr>
<td>Mechanical Technology</td>
<td>200</td>
<td>5</td>
<td>2.50%</td>
<td>1</td>
<td>0.50%</td>
<td>2.50%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>600</strong></td>
<td><strong>20</strong></td>
<td><strong>3.33%</strong></td>
<td><strong>1</strong></td>
<td><strong>0.17%</strong></td>
<td><strong>3.33%</strong></td>
</tr>
</tbody>
</table>

The JPO study also examined whether the rejection identified under Article 29bis was made based on a principle of strict novelty (“the same”) or enlarged novelty (“substantially the same”). In the chemistry, life science, and material science area, four of five Article 29bis rejections were based on SPA that was the same, while one of five was based on SPA that was substantially the same. The same proportion was seen in the mechanical technology field, while all of the Article 29bis rejections made in the electronic technology field were based on SPA that was same. It is also noteworthy to mention that, in cases of enlarged novelty, additional references may be used to prove that the differences are minor ones; however, these references were not counted in the study.

d. Korea

The Korean Patent Office (KIPO) examined all first office actions issued in 2015 across three top level International Patent Classification (IPC) sections B (mechanical), C (chemical) and H (electrical) using an automated process. The IPC is a hierarchical classification system used to classify patent documents according to the technical fields to which they pertain. The highest
hierarchical levels, symbolized as sections “A” through “H,” are tied to broad distinct technical fields (e.g., Section C deals with “Chemistry and Metallurgy,” while C21 deals with “Metallurgy of Iron”).

In cases in which conflicting applications were cited, KIPO examiners cite only one reference. Korea applies “novelty only” to determining the patentability of applications based on conflicting applications. Similar to the Japan’s practice, “substantially same” inventions also lack novelty under Korean patent law. KIPO was not able to collect statistics or any data on self collision since KIPO examiners do not cite or record secret prior art of the same inventive entity.

Table 5 demonstrates the frequency of rejections based on secret prior art.

Table 5: Korean Intellectual Property Office’s Secret Prior Art Rejections in 2015, by Technology Area

<table>
<thead>
<tr>
<th>Technology</th>
<th>Sample Size</th>
<th>SPA Rejections at First Action</th>
<th>% of SPA Rejections (Novelty)</th>
<th>Number of Double-Patenting Rejections</th>
<th>% of Double-Patenting Rejections</th>
<th>Total % of SPA Rejections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemistry</td>
<td>20196</td>
<td>58</td>
<td>0.29%</td>
<td>177</td>
<td>0.88%</td>
<td>0.29%</td>
</tr>
<tr>
<td>Electrical</td>
<td>36431</td>
<td>69</td>
<td>0.19%</td>
<td>177</td>
<td>0.49%</td>
<td>0.19%</td>
</tr>
<tr>
<td>Mechanical</td>
<td>28208</td>
<td>57</td>
<td>0.20%</td>
<td>95</td>
<td>0.34%</td>
<td>0.20%</td>
</tr>
<tr>
<td>Total</td>
<td>84835</td>
<td>184</td>
<td>0.22%</td>
<td>449</td>
<td>0.53%</td>
<td>0.22%</td>
</tr>
</tbody>
</table>

**e. United Kingdom**

The United Kingdom’s Intellectual Property Office (UKIPO) selected 200 cases in each technology area: chemistry, electrical, and mechanical. Fields of technology were determined by running the First Inventive IPC8 classification of each identified application through WIPO’s IPC8 Technology Concordance and selecting applications falling into one of “Chemistry”, “Electrical Engineering” and “Mechanical Engineering” from a list of five potential sectors (the others being “Instruments” and “Other.”)²

An automated process was run to find applications in which “secret prior art” (category “X” and “E”) documents had been cited at any stage. Those applications found to have such citations were then individually checked to find: (a) the number of applications containing rejections based on the secret prior art in the first examination report; (b) the number of secret prior art citations relied upon in each case; and (c) the number of those secret prior art citations from the same applicant. Secret prior art citations, cited under section 2(3) of the UK Patents Act, may

only be cited for novelty. Therefore, references to them in an examination report will only be in relation to assessing novelty, not inventive step.

Table 6 provides the number of applications containing rejections based on secret prior art. Table 7 gives the number of secret prior art citations relied upon in each case, and Table 8 gives the number of secret prior art citations from the same applicant. For comparison purposes only, Table 9 gives the percentages of applications with secret prior art, cited at any stage, for all applications first examined in 2015. Because these applications have not been individually checked, it is not possible to determine if citations were cited at the first examination stage, but the results give a rough indication of the proportion of cases on which secret prior art was cited.

Table 6: U.K. Intellectual Property Office’s Applications with Rejections Based on Secret Prior Art at First Exam Stage in 2015, by Technology Area

<table>
<thead>
<tr>
<th>Technology</th>
<th>Sample Size</th>
<th>SPA Rejections at First Exam</th>
<th>% of SPA Rejections (Novelty)</th>
<th>Number of Same-applicant SPA Rejections</th>
<th>% of Same-applicant SPA Rejections</th>
<th>% of SPA at 1st Exam that are SPA from the Same Applicant</th>
<th>Total % of SPA Rejections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemistry</td>
<td>200</td>
<td>9</td>
<td>4.50%</td>
<td>3</td>
<td>1.50%</td>
<td>33.3%</td>
<td>4.50%</td>
</tr>
<tr>
<td>Electrical</td>
<td>200</td>
<td>10</td>
<td>5.00%</td>
<td>1</td>
<td>0.50%</td>
<td>10.0%</td>
<td>5.00%</td>
</tr>
<tr>
<td>Mechanical</td>
<td>200</td>
<td>7</td>
<td>3.50%</td>
<td>2</td>
<td>1.00%</td>
<td>28.6%</td>
<td>3.50%</td>
</tr>
<tr>
<td>Total</td>
<td>600</td>
<td>26</td>
<td>4.33%</td>
<td>6</td>
<td>1.00%</td>
<td>23.1%</td>
<td>4.33%</td>
</tr>
</tbody>
</table>

Table 7: U.K. Intellectual Property Office’s Number of Secret Prior Art References in 2015, by Technology Area

<table>
<thead>
<tr>
<th>Technology</th>
<th>Number of Secret Prior Art References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Chemistry</td>
<td>8</td>
</tr>
<tr>
<td>Electrical</td>
<td>6</td>
</tr>
<tr>
<td>Mechanical</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
</tr>
</tbody>
</table>
Table 8: U.K. Intellectual Property Office’s Number of Secret Prior Art References from Same Applicant (“Self-colliding”) in 2015, by Technology Area

<table>
<thead>
<tr>
<th>Technology</th>
<th>Number of Secret Prior Art References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Chemistry</td>
<td>3</td>
</tr>
<tr>
<td>Electrical</td>
<td>0</td>
</tr>
<tr>
<td>Mechanical</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>5</td>
</tr>
</tbody>
</table>

Table 9: U.K. Intellectual Property Office’s Percentage of Applications Citing Secret Prior Art at Any Stage in 2015, by Technology Area

<table>
<thead>
<tr>
<th>Technology</th>
<th>SPA Citations at Any Stage</th>
<th>From Same Applicant</th>
<th>SPA Citations at Search Stage(^a)</th>
<th>From Same Applicant</th>
<th>SPA Citations at Exam Stage(^b)</th>
<th>From Same Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemistry</td>
<td>4.90%</td>
<td>1.50%</td>
<td>3.00%</td>
<td>0.80%</td>
<td>1.90%</td>
<td>0.80%</td>
</tr>
<tr>
<td>Electrical</td>
<td>4.90%</td>
<td>1.50%</td>
<td>1.60%</td>
<td>0.20%</td>
<td>3.20%</td>
<td>1.30%</td>
</tr>
<tr>
<td>Mechanical</td>
<td>4.70%</td>
<td>1.20%</td>
<td>1.80%</td>
<td>0.70%</td>
<td>3.00%</td>
<td>0.50%</td>
</tr>
<tr>
<td>Instruments/other</td>
<td>4.20%</td>
<td>0.50%</td>
<td>1.80%</td>
<td>0.30%</td>
<td>2.40%</td>
<td>0.20%</td>
</tr>
<tr>
<td>Total</td>
<td>4.50%</td>
<td>1.00%</td>
<td>1.90%</td>
<td>0.40%</td>
<td>2.70%</td>
<td>0.60%</td>
</tr>
</tbody>
</table>

\(^a\) Although this column references instances in which SPA was first cited at the search stage, the SPA may also have been cited at examination stage.

\(^b\) This column references SPA citations at the examination stage, including the first examination and subsequent examinations.

f. **United States**

The USPTO selected 200 cases in each of the following areas: 1. Biotechnology and Chemistry (e.g., Organic Chemistry, Chemical and Materials Engineering, Pharmaceuticals); 2. Electrical (e.g., Computer Architecture, Software, Computer Networks, Communications, Semiconductors, Electrical and Optical Systems and Components); and 3. Mechanical (e.g., Manufacturing, Products, Agriculture, Mechanical Engineering). More specifically, the Biotechnology and Chemistry cases were selected from cases examined by USPTO Technology Centers (TC) 1600 and 1700, Electrical cases from TC 2100, 2400, 2600, and 2800, and Mechanical from TC 3700. In addition, applications were limited to those that have been published and received a first action on the merits in 2015.
As described above, the America Invents Act (AIA) made a number of changes to U.S. law regarding the treatment of conflicting applications, including abolishment of the Hilmer doctrine. Under the Hilmer doctrine, pre-AIA 35 U.S.C. § 102(e) limited the effective filing date for U.S. patents (and published applications) as prior art to their earliest U.S. filing date. In contrast, AIA 35 U.S.C. § 102(d) provides that if the U.S. patent document claims priority to one or more prior-filed foreign or international applications, the patent or published application was effectively filed on the filing date of the earliest such application that describes the subject matter. In order to account for this change of law, our sample was limited to cases examined under the AIA.

Once the pool of applications was randomly selected, each case was manually reviewed to determine whether either a novelty (35 U.S.C. § 102(a)(2)) or obviousness (35 U.S.C. § 103) rejection was made based on secret prior art. We also tallied the number of references used to make any such rejection.

As is described above, under U.S. patent law, secret prior art is applicable to the determination of both novelty and non-obviousness. In reviewing the data shown in Table 10, secret prior art is cited more often in obviousness-type rejections than in lack of novelty rejections. Regardless of this distinction, both types of rejections based on secret prior art occur relatively frequently: 2.5% of biotechnology and chemistry cases, 18% of electrical cases, and 9.5% of mechanical cases.

**Table 10: USPTO Rejections Based on Secret Prior Art in First Action on the Merits in 2015, by Technology Area**

<table>
<thead>
<tr>
<th>Technology</th>
<th>Sample Size</th>
<th>Number of SPA Novelty Rejections (Novelty)</th>
<th>% of SPA Novelty Rejections</th>
<th>Number of SPA Obviousness Rejections</th>
<th>% of SPA Obviousness Rejections</th>
<th>Total % SPA Rejections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology and Chemistry</td>
<td>200</td>
<td>0</td>
<td>0.00%</td>
<td>5</td>
<td>2.50%</td>
<td>2.50%</td>
</tr>
<tr>
<td>Electrical</td>
<td>200</td>
<td>10</td>
<td>5.00%</td>
<td>26</td>
<td>13.00%</td>
<td>18.0%</td>
</tr>
<tr>
<td>Mechanical</td>
<td>200</td>
<td>5</td>
<td>2.50%</td>
<td>14</td>
<td>7.00%</td>
<td>9.50%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>600</strong></td>
<td><strong>15</strong></td>
<td><strong>2.50%</strong></td>
<td><strong>45</strong></td>
<td><strong>7.50%</strong></td>
<td><strong>10%</strong></td>
</tr>
</tbody>
</table>

In addition to tallying the total number of rejections relying on secret prior art, the USPTO noted the total number of references used to make obviousness-type rejections. As shown in Table 11, examiners typically combined secret part art with one or two other references for a total of two to three references per rejection.
Table 11: USPTO Number of References Used in Obviousness-type Secret Prior Art Rejections in 2015, by Technology Area

<table>
<thead>
<tr>
<th>Technology</th>
<th>Secret Prior Art References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Biotechnology and Chemistry</td>
<td>1</td>
</tr>
<tr>
<td>Electrical</td>
<td>1</td>
</tr>
<tr>
<td>Mechanical</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>3</strong></td>
</tr>
</tbody>
</table>

VI. Preliminary Analysis of Results

Table 12 summarizes the data provided by the participating offices for the mechanical, electrical, and biotechnology/chemistry technology areas, including, when possible, the basis for the refusal, i.e., lack of novelty or obviousness/inventive step.

Table 12: Frequency of Citation of Secret Prior Art by Office, in 2015

<table>
<thead>
<tr>
<th>Technology</th>
<th>Office</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CIPO⁴</td>
</tr>
<tr>
<td></td>
<td>Novelty</td>
</tr>
<tr>
<td>Biotechnology and Chemistry</td>
<td>0.86%</td>
</tr>
<tr>
<td>Electrical</td>
<td>0.00%</td>
</tr>
<tr>
<td>Mechanical</td>
<td>1.07%</td>
</tr>
<tr>
<td><strong>Total (Avg. %)</strong></td>
<td><strong>0.64%</strong></td>
</tr>
</tbody>
</table>

3 The Canadian data is represented under the “Biotechnology and Chemistry” heading in Table 12 by combining the results reported by CIPO in the chart in Section 3(a) above under the “Biotech,” “General Chemistry,” and “Organic Chemistry” headings.

4 The results below only take into account objections under 28.2(1)(c) or (d) of the Canadian Patent Act.
Table 12 reveals that the frequency of citation of secret prior art for novelty purposes, irrespective of the technology or office, ranges from 0% on the low end to as high as 6.0%, with an average of 2.48%. While these percentages are somewhat low in absolute terms, they tell a rather different story when scaled in relative terms.

On a technology basis, Biotechnology and Chemistry represented the largest frequency range across offices, ranging between 0% and 6.0%, with an average of 2.36% followed by Electrical (0%-5%, average 2.95%) and Mechanical (0.20%-3.5%, average 2.13%). Data on the number of filings in the respective technology areas for each participating office does not appear to be readily available but, if obtained, could provide a basis for determining the potential number of applications impacted across the offices on an annual basis.

On an office-by-office basis, UKIPO reported the highest overall percentage of secret prior art-based novelty citations of 4.33% with the EPO following closely behind with an overall percentage of 3.83%. The next nearest office in terms of overall average percentage was the JPO at 3.33%, the USPTO at 2.5%, CIPO at 0.64%, and KIPO at 0.22%.

It is interesting to note that the UKIPO and EPO, which both apply a strict, novelty-only standard in accordance with the EPC, reported the highest overall percentages, as well as the fact that the EPO and UKIPO reported 6.0% and 4.5%, respectively, in Biotechnology whereas the USPTO reported 0%. Of course, the situation is a bit different if USPTO refusals based on obviousness are also considered, in which case Biotechnology jumps to 2.5% and Electrical to 13%. However, this also begs the question as to how much higher the percentages would be at the EPO and the UKIPO (and more broadly, throughout EPC Contracting States) if the EPC also permitted secret prior art to be used to refuse applications for lack of inventive step, although divergences in practice would make a meaningful comparison of such data difficult. This question has been raised in past Tegernsee and Group B+ studies on conflicting applications in terms of the potential impact different approaches to conflicting application treatment have on the growth or mitigation of “patent thickets.”

The Tegernsee Report also indicated that there was a perception on the part of respondents that patent thickets (as defined in the questionnaire as a cluster of patents that may or may not be related or subject to common ownership, and which have claims of overlapping scope) were less prevalent in the European market than in some other markets (See Final Consolidated Tegernsee Report (2014), p. 61, Chart No. 3.11). Given that the practice at the EPO is based on the narrowest definition of the relevance of secret prior art, but does not include anti-self-collision, this outcome raised the issue of the role of anti-self-collision in the growth or mitigation of “patent thickets”.

The study also attempted to investigate at least some aspects of the use of secret prior art through data gathered by the offices on the number of instances of anti-self-collision/double patenting occurring in the sampled applications. Although several offices reported information in this
respect, the divergence in practice makes it difficult for other offices to report rates of self-collision thereby making a comparison of data impossible. Because of this, it cannot be assessed how many applications may have proceeded to grant in these jurisdictions that would have been refused at the EPO, UKIPO, and in other national offices of the EPC Contracting States based on SPA. One interesting aspect, however, is the number of instances of citation of secret prior art emanating from the same applicant at the EPO, and UKIPO, with respective rates of 56.5% and 23.1%. This outcome raises the issue of the impact of anti-self-collision on the system. Further exploration of this issue could help to identify the impact of these practices on the number of patents with overlapping scope granted to related or different parties, and thus provide a clearer picture as to their relationship to patent thickets.

Along similar lines, an attempt was made to collect data on the number of references cited in secret prior art–based refusals, but the limited data sets (largely a function of the fact that most offices do not permit secret prior art to be combined with other prior art to make any refusal) coupled with the different practices in each jurisdiction, make direct comparisons difficult. However, the USPTO data, representing the only office of those participating that applies secret prior art for novelty and non-obviousness determinations, do provide insight into what effects a similar practice might have in another office. The USPTO reports that in the observed refusals based on obviousness, the refusals most frequently involved two or three references, at least one of which was secret prior art. One implication from the USPTO data may be that reliance on a single secret prior art reference to establish obviousness may be insufficient in many cases, raising a question whether the option of adopting a novelty + inventive step with “no-mosaic” approach can be readily imported into jurisdictions, specifically the US, without more extensive changes in either law or practice.

Because this analysis is preliminary, at a minimum, further consultations among the offices to discuss variations and nuances of their laws, practices, and methodologies are necessary. In addition, given the initial sample size, further investigation may be required to refine these numbers and verify the accuracy of the data. For example, it may be necessary to expand the sample size to determine whether the percentages identified in the preceding paragraphs are accurate. It may also be worthwhile to identify and focus on certain “crowded” technologies to ensure adequate representation in the study, as this may reveal an increase in the reported percentages of secret prior art rejections. Further, it may be valuable to explore the number of common patent family members among the offices, which could shed more light on the importance of these numbers for work sharing purposes, among other things.
VII. Conclusion
In order to better inform the Group B+ Subgroup on Harmonization as they discuss potential options for the harmonization of treatment of conflicting applications, the Conflicting Applications Work Stream (CAWS) proposed a study to determine the frequency and type of patentability rejections based on secret prior art. This study, although limited in some ways due to variations in practices and small sample sizes, provides valuable insight into the frequency by which examiners make rejections based on secret prior art. As Group B+ considers proposals going forward, this data will be a useful tool in better understanding the impact of any proposed changes. In this regard, the results of this study will better assist both offices and stakeholders as they grapple with proposing rules that balance the need to protect incremental innovation with ensuring that multiple patents are not granted on the same or similar inventions and patent rights are not unjustifiably extended. To date, the analysis is preliminary in nature and further discussion among the participating offices is necessary for a more comprehensive and thorough report.
Appendix 1: Explanation of SPA Rejection Practice in Japan

Where the claimed invention is substantially identical to a matter originally disclosed in a “secret” prior art as filed as a result of comparison between them, the examiner determines that the claimed invention shall not be granted a patent under the Article 29bis.

In cases where there are two or more claims, the examiner makes a determination on the requirements for the Article 29bis on a claim-by-claim basis.

(See 3. in the Examination Guidelines, Part III, Chap. 3)

The examiner determines that the claimed invention is "substantially identical" to the matter disclosed in the “secret” prior art under the Article 29bis in the following case (i) or (ii):

(i) Where the claimed invention is not different from the matter disclosed in the “secret” prior art. (This is the case where the claimed invention lacks novelty\(^5\) in view of the “secret” prior art.)

(ii) Where although the claimed invention is different from the matter disclosed in the “secret” prior art, the difference identified is a minor one, which is mere addition, deletion or conversion of “well-known arts” and does not bring any new technical effects. (This is the case where the claimed invention is novel but lacks "enlarged novelty" over the “secret” prior art.)

(See 3.2. in the Examination Guidelines, Part III, Chap. 3)

In the Examination Guidelines in Japan, “well-known art” is defined as technical matter which is conventional in the relevant technical field. For example, it includes the following ones:

(i) Technical matter which is shown in a great number of prior art documents or webpages etc.

(ii) Technical matter which is widely known throughout the industry

(iii) Technical matter which so well-known that it is needless to present any evidences

(See “Note 1” in 2. in the Examination Guidelines, Part III, Chap. 2, Sec. 2.)

When the examiner refers to well-known art as a basis of the knowledge (the knowledge of state of the art including common general knowledge etc.) or ability (the ability to use ordinary technical means for research and development, and normal creative ability) of a person skilled in the art for the reasoning in notices of reasons for refusal or decisions of refusal, they should show evidence except when it is not needed to do so.

(See 5.3 (3) in the Examination Guidelines, Part III, Chap. 2, Sec. 3.)

---

\(^5\) It should be noted that this "novelty" differs from (normal cases of) novelty (i.e. Article 29(1)) which is determined based on a prior art "publicly known" at the time of filing of the present application.
In notifying reasons for refusal based on the violation of requirements for the Article 29bis, in order for applicants to clearly understand the reasons for refusal, documents other than the “secret” prior art may be referred to as evidences to support the fact that the differences between the claimed inventions and the matter disclosed in the “secret” prior art is minor one, if needed. It should be noted that, even in such a case, the references to those documents do not mean that the documents would be combined with the “secret” prior art, which is the case where an inventive step is denied.

**Example of Court Decision**


In this case, although a *prima facie* difference was identified between the claimed invention and the matter disclosed in a “secret” prior art, the difference was that a well-known art, for which two patent documents, i.e., JP 2000-305980A and JP H11-195039A, were referred to as evidences, was merely added to the matter disclosed in the “secret” prior art, and did not bring any new technical effect. The court therefore concluded that the claimed invention was *substantially* identical to the matter disclosed in the “secret” prior art.
Appendix 2: Examples of Substantial Identicalness in Korea

In KIPO, an invention lacks novelty if it is identical or substantially identical to a prior art.

“Substantially identical (or substantially same)” refers to the case where non-fundamental matters (secondary matters), not the main technical ideas of the invention, are different between the subject matter of the claimed invention and the subject matter of the prior art, such as mere differences in expression, recognition of effects, purposes or use as well as trivial change in embodiment or limitation of use, etc.

The following are some examples of ‘substantial identicalness’ or ‘substantial sameness’ as discussed in the KIPO examination guidelines.

1. Mere difference in expression:

(Example) The method of desalination of sea water and the method of concentration of sea water by separating water from sea water through the insertion of a refrigerant undissolved in sea water.

2. Mere difference in recognition of effects:

(Example) As for an invention disclosing a conductor covered with polyethylene, where differences in recognition of the effects of the invention exist since a prior application discloses that the invention has greater electric insulation, whereas a subsequent application discloses that the invention exhibits better high frequency properties.

3. Mere differences in use:

(Example) A plasticizer of polyvinyl chloride comprising compound B and A ultraviolet light absorber of polyvinyl chloride comprising compound B.

(Example) A method of spraying chemical A on the fields to repel hares (Hare Repellent A) and A method of spraying chemical A on the fields to repel deer (Deer Repellent A).

4. Simple limitation of use:

(Example) A net comprising threads with flat cross sections and A fish net comprising threads with flat cross sections.

5. Trivial changes in elements:

Trivial changes in the elements of the inventions refer to the case where the element of the invention is changed and such changes constitute mere substitution, addition or deletion of the technical means which could be easily made by a person skilled in the art as the detailed means to achieve the purpose of the invention and the changes do not lead to significant changes in the purposes and effects of the inventions.
5.1. Change of common means:

(Example) A manufacturing process of clarifying pure fruit juice by using bentonite and then vacuum freeze drying the juice into powdered fruit juice and a manufacturing process of clarifying pure fruit juice by using diatomite then vacuum freeze drying the juice into powdered fruit juice.

5.2. Addition or deletion of Common Means:

(Example) A manufacturing process of P-nitrotoluidine by nitrifying toluene and A manufacturing process of P-nitrotoluene by nitrifying toluene and then returning it back to P-toluene (a manufacturing process of P-toluidine by returning P-nitrotoluene back is a well-known common means).

5.3. Change of material or substitution of equivalent:

(Example) A foundation pile with blades attached on the circumference of a concrete pile and A foundation pile with blades attached on the circumference of a pile.

5.4. Trivial limitation or change of figures, numbers or sequences:

Trivial limitation or change of figures, numbers or sequences refers to the case where changes constitute mere limitation or change of figure, numbers or sequences that a person skilled in the art would commonly apply to based on the purpose and other elements and such changes do not lead to significant differences in the purposes and effects of the invention.

Under the America Invents Act (AIA), the treatment of conflicting applications in the United States is governed, in part, by 35 U.S.C. § 102(a)(2), which provides that a claimed invention is patentable unless the claimed invention was described in a patent or in a published patent application that names another inventor and was effectively filed before the effective filing date of the claimed invention. This legal authority prevents patents from issuing on later-filed applications when an earlier-filed application by another inventor discloses the claimed invention. As such, an examiner is able to apply prior art against an application for purposes of a lack of novelty even if the prior art reference was not published at the time the application under examination was filed.

In contrast to the laws of the other participating jurisdictions, in the United States conflicting applications may be considered by themselves or in combination with other items of “prior art,” including other conflicting applications, for purposes of determining whether an invention in a later-filed application would have been obvious. The section governing obviousness, 35 U.S.C. § 103, provides that a patent for a claimed invention may not be obtained if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Because all of the subject matter that is prior art under Section 102 can be used for obvious determinations under Section 103, the prior art effect of conflicting applications is the same for deterring lack of novelty and obviousness.

The distinction between rejections based on 35 U.S.C. § 102 and those based on 35 U.S.C. § 103 should be kept in mind. Under the former, the claim is anticipated by the reference. No question of obviousness is present. In other words, for anticipation under 35 U.S.C. § 102, the reference must teach every aspect of the claimed invention either explicitly or impliedly. Any feature not directly taught must be inherently present. Whereas, in a rejection based on 35 U.S.C. § 103, the reference teachings must somehow be modified in order to meet the claims. The modification must be one which would have been obvious to one of ordinary skill in the art at the time the invention was filed. See MPEP §§ 2131 - 2146 and 2150 - 2159.04 for guidance on patentability determinations under 35 U.S.C. § 102 and § 103.

**Novelty Rejections under 35 U.S.C. § 102 (a)(2)**

Specifically, under 35 U.S.C. 102(a)(2), examiners may reject claims using US patents, published US applications, and published PCT applications designating the US as long as the reference is by a different inventive entity and has an effective filing date prior to the application under examination. However, any prior art which is only available under 35 U.S.C. § 102(a)(2) is subject to the three exceptions identified under 35 U.S.C. § 102(b)(2) and may be disqualified by
the applicant if the art is used against their application. The exceptions specify that a disclosure shall not be part of the prior art to a claimed invention under (a)(2) if:

(a) the subject matter disclosed was obtained directly or indirectly from the inventor or a joint inventor;

(b) the subject matter disclosed had, before such subject matter was effectively filed under subsection (a)(2), been publicly disclosed by the inventor or a joint inventor or another who obtained the subject matter disclosed directly or indirectly from the inventor; or

(c) the subject matter disclosed and the claimed invention, not later than the effective filing date of the claimed invention, were owned by the same person or subject to an obligation of assignment to the same person.

When rejecting a claim under 35 U.S.C. 102, examiners will provide specific references in the prior art for each claim limitation and will also provide claim interpretation where necessary to show how the reference anticipates the limitation.

**Obviousness Rejections under 35 U.S.C. § 103**

As noted above, 35 U.S.C. § 103 authorizes a rejection where, to meet the claim, it is necessary to modify a single reference or to combine it with one or more other references to establish obviousness. USPTO practice provides that in order to establish a rebuttable case of obviousness, an examiner should set forth in the Office Action:

(a) the relevant teachings of the prior art relied upon, preferably with reference to the relevant column or page number(s) and line number(s) where appropriate,

(b) the difference or differences in the claim over the applied reference(s),

(c) the proposed modification of the applied reference(s) necessary to arrive at the claimed subject matter, and

(d) an explanation as to why the claimed invention would have been obvious to one of ordinary skill in the art at the time the invention was made. MPEP 706.02(j).

Regarding (a)-(c), the examiner communicates their understanding of the capabilities of the prior art as they relate to the examined claims, how the prior art would need to be modified, and what the modification would entail. Element (d) requires that “To support the conclusion that the claimed invention is directed to obvious subject matter, either the references must expressly or impliedly suggest the claimed invention or the examiner must present a convincing line of reasoning as to why the artisan would have found the claimed invention to have been obvious in light of the teachings of the references.” Ex parte Clapp, 227 USPQ 972, 973 (Bd. Pat. App. & Inter. 1985).
While the examiner may rely on any evidence to present a convincing line of reasoning for obviousness, MPEP sections 2144.04 – 2144.09 provide accepted examples of obvious modifications. A few examples of which include:

I. *Aesthetic Design Changes:* “Matters relating to ornamentation only which have no mechanical function cannot be relied upon to patentably distinguish the claimed invention from the prior art.”

II. *Automating a Manual Activity:* “Broadly providing an automatic or mechanical means to replace a manual activity which accomplished the same results is not sufficient to distinguish over the prior art.”

III. *Changes in Size, Shape, or Sequence of Adding Ingredients:* “Mere scaling up of a prior art process capable of being scaled up, if such were the case, would not establish patentability in a claim to an old process so scaled.”

IV. *Changes in Sequence of Adding Ingredients:* “Selection of any order of performing process steps is prima facie obvious in absence of new or unexpected results.”

V. *Overlapping, Approaching, and Similar Ranges, Amounts, and Proportions:* “Where the claimed ranges overlap or lie inside ranges disclosed by the prior art a prima facie case of obviousness exists.”

VI. *Close Structural Similarity Between Chemical Compounds:* “An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties.”

It is important for an examiner to properly communicate the basis for a rejection so that the issues can be identified early and the applicant can be given fair opportunity to reply. Furthermore, if an initially rejected application issues as a patent, the rationale behind an earlier rejection may be important in interpreting the scope of the patent claims. Since issued patents are presumed valid (35 U.S.C. § 282) and constitute a property right (35 U.S.C. § 261), the written record must be clear as to the basis for the grant. MPEP 706.02(j)

**Conclusion**

In the United States, legal authority prevents patents from issuing on later-filed applications when an earlier-filed application by another inventor teaches the claimed invention even if the prior art reference was not publicly available at the time the application under examination was filed. This policy is considered to encourage applicants to bring subject matter to the public’s attention as quickly as possible by filing as early as possible. A second filer should not benefit from delaying their application and are therefore subject to evidence and disclosures which have
filed first and have subsequently published. Because these prior art references are evidence of knowledge, skill, and innovation in the art prior to the filing date of the application under examination, they can be used to demonstrate both lack of novelty by teaching every aspect of the claim as required by 35 U.S.C. 102 or teach how combinations or modifications of references which would have been obvious as set forth in 35 U.S.C. 103.